Abstract
MALIGNANT hyperthermia (MH) is a potentially lethal condition in which sustained muscle contracture, with attendant hypercatabolic reactions and elevation in body temperature, are triggered by commonly used inhalational anaesthetics and skeletal muscle relaxants1. In humans, the trait is usually inherited in an autosomal dominant fashion2, but in halothane-sensitive pigs3with a similar phenotype, inheritance of the disease is autosomal recessive or co-dominant. A simple and accurate non-invasive test for the gene is not available and predisposition to the disease is currently determined through a halothane- and/or caffeine-induced contracture test on a skeletal muscle biopsy4,5. Because Ca2+ is the chief regulator of muscle contraction and metabolism, the primary defect in MH is believed to lie in Ca2+ regulation1,6. Indeed, several studies indicate a defect in the Ca2+ release channel of the sarcoplasmic reticulum7–12, making it a prime candidate for the altered gene product in predisposed individuals. We have recently cloned complementary DNA and genomic DNA encoding the human ryanodine receptor13 (the Ca2+-release channel of the sarcoplasmic reticulum) and mapped the ryanodine receptor gene(RYR) to region q13.1 of human chromosome 19 (ref. 14), in close proximity to genetic markers that have been shown to map near the MH susceptibility locus in humans15 and the halothane-sensitive gene in pigs16. As a more definitive test of whether the RYR gene is a candidate gene for the human MH phenotype, we have carried out a linkage study with MH families to determine whether the MH phenotype segregates with chromosome 19q markers, including markers in the RYR gene. Co-segregation of MH with RYRmarkers, resulting in a lod score of 4.20 at a linkage distance of zero centimorgans, indicates that MH is likely to be caused by mutations in the RYR gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Britt, B. A. in Malignant Hyperthermia (ed. Britt, B. A.) 11–42 (Martinus Nijhoff, Boston, 1987).
Kalow, W. in Malignant Hyperthermia (ed. Britt, B. A.) 155–180 (Martinus Nijhoff, Boston, 1987).
Harrison, G. G. in Malignant Hyperthermia (ed. Britt, B. A.) 103–136 (Martinus Nijhoff, Boston, 1987).
Kalow, W., Britt, B. A., Terreau, M. E. & Haist, C. Lancet ii, 895–898 (1970).
Britt, B. A. in Malignant Hyperthermia Current Concepts (eds Nalda Felipe, M. A., Gottman, S. & Khambatta, H. J.) 53–96 (Norman, Bad Homburg, 1989).
Iaizzo, P. A., Klein, W. & Lehmann-Horn, F. Pflugers Arch. 411, 648–653 (1988).
Endo, M. et al. Biomed Res. 4, 83–92 (1983).
Ohnishi, S. T., Taylor, S. & Gronert, G. A. FEBS Lett. 161, 103–107 (1983).
Nelson, T. E. J. clin. Invest. 72, 862–873 (1983).
Kim, D. H. et al. Biochim. biophys. Acta 775, 320–327 (1984).
Mickelson, J. R. et al. J. biol. Chem. 263, 9310–9315 (1988).
O'Brien, P. J. Can. J. vet Res. 50, 318–328 (1986).
Zorzato, F. et al. J. biol. Chem. 265, 2244–2256 (1989).
MacKenzie, A. E. et al. Am. J. hum. Genet. (submitted).
McCarthy, T. V. et al. Nature 343, 562–564 (1990).
Davies, W., Harbitz, I., Fries, R., Stranzinger, G. & Hauge, J. G. An. Genet. 19, 203–212 (1988).
Smeets, H. et al. Nucleic Acids Res. 17, 3324 (1989).
Hulsebos, T., Westphal, H., Peek, R., Coerwinkel, M. & Wieringa, B. Nucleic Acids Res. 14, 7137 (1986).
Smeets, H. et al. Nucleic Acids Res. 17, 3325 (1989).
Smeets, H. et al. Nucleic Acids Res. 15, 8120 (1987).
Schepens, J. et al. Nucleic Acids Res. 15, 3193 (1987).
Schepens, J., Smeets, H., Hulsebos, T., Brunner, H. & Wieringa, B. Nucleic Acids Res. 15, 3192 (1987).
Humphries, S. E. et al. Molec. Biol. Med. 1, 463–471 (1983).
Schonk, D. et al. Genomics 4, 384–396 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacLennan, D., Duff, C., Zorzato, F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343, 559–561 (1990). https://doi.org/10.1038/343559a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/343559a0
This article is cited by
-
The 100 most cited articles in malignant hyperthermia
Anesthesiology and Perioperative Science (2023)
-
Ryanodine receptor RyR1-mediated elevation of Ca2+ concentration is required for the late stage of myogenic differentiation and fusion
Journal of Animal Science and Biotechnology (2022)
-
Loss-of-rescue of Ryr1I4895T-related pathology by the genetic inhibition of the ER stress response mediator CHOP
Scientific Reports (2022)
-
Molecular and cellular basis of genetically inherited skeletal muscle disorders
Nature Reviews Molecular Cell Biology (2021)
-
Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature
Skeletal Muscle (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.